ProCE Banner Activity

Contemporary Myelofibrosis Care: Experts Answer Your Questions

Clinical Thought

Review answers to questions posed to experts about the management of patients with myelofibrosis, including their thoughts about symptom control with JAK inhibitors.

Released: May 18, 2023

Share

Faculty

Prithviraj Bose

Prithviraj Bose, MD

Associate Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Stephen Oh

Stephen Oh, MD, PhD

Associate Professor of Medicine
Co-Chief, Division of Hematology
Washington University School of Medicine
Saint Louis, Missouri

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from CTI BioPharma Corp., GSK, and Incyte Corporation.

CTI BioPharma Corp

GSK

Incyte Corporation

Disclosure

Primary Author

Prithviraj Bose, MD

Associate Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Prithviraj Bose, MD: consultant/advisor/speaker: AbbVie, Blueprint, Bristol Myers Squibb, Cogent, CTI, GlaxoSmithKline, Incyte, Karyopharm, MorphoSys, Novartis, PharmaEssentia; researcher: Blueprint, Bristol Myers Squibb, Cogent, CTI, Disc Medicine, Incyte, Ionis, Kartos, MorphoSys, Telios.

Stephen Oh, MD, PhD

Associate Professor of Medicine
Co-Chief, Division of Hematology
Washington University School of Medicine
Saint Louis, Missouri

Stephen Oh, MD, PhD: consultant/advisor/speaker: AbbVie, Celgene/Bristol Myers Squibb, Cogent, Constellation, CTI, Geron, Incyte, Sierra Oncology/-GlaxoSmithKline.